Fresenius Medical Care AG (ETR:FME – Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of €45.75 ($53.20) and traded as high as €47.23 ($54.92). Fresenius Medical Care shares last traded at €47.17 ($54.85), with a volume of 466,778 shares traded.
Fresenius Medical Care Stock Performance
The firm has a market cap of $13.75 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 0.42 and a beta of 0.86. The company has a 50 day simple moving average of €44.14 and a 200-day simple moving average of €45.75. The company has a debt-to-equity ratio of 82.24, a current ratio of 1.37 and a quick ratio of 0.80.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
- Five stocks we like better than Fresenius Medical Care
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Warner Bros. Bidding War Potential: How High Could WBD Shares Go?
- What is a buyback in stocks? A comprehensive guide for investors
- Analysts Eye 30% Upside in Netflix After Q3 Earnings Crash
- What Makes a Stock a Good Dividend Stock?
- O’Reilly Automotive’s Stock Price Uptrend Will Continue in 2026
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.
